Market Overview

Senseonics Announces Two Positive Blue Cross Blue Shield Coverage Decisions for Eversense CGM

Share:

--Blue Cross Blue Shield of Massachusetts and Idaho coverage decisions add nearly 3.5 Million covered lives for Eversense CGM--

Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Blue Cross Blue Shield of Massachusetts and Blue Cross Blue Shield of Idaho are now providing coverage for Eversense CGM. These recent coverage decisions add to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider's time for the in-office sensor placement.

Blue Cross Blue Shield of Massachusetts is a community-focused, tax-paying, not-for-profit health plan headquartered in Boston serving nearly three million members across four states including Massachusetts, southern New Hampshire, southern Maine and Rhode Island. Blue Cross of Idaho is a not-for-profit mutual insurance company based in Meridian, Idaho, serving more than half a million members.

The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose and can be removed, recharged and re-adhered without discarding the sensor. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.

"We are pleased that both Blue Cross Blue Shield of Massachusetts and Idaho have recognized Eversense CGM as one of their diabetes management tools and also recognize the value it brings to their patients with diabetes," said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. "With each new coverage decision, we are able to reduce the barriers and help thousands of patients experience the freedom that Eversense brings for up to 90 days of continuous glucose readings. This kind of proactive information helps empower patients to actively manage their diabetes."

Patients who are interested in getting started on Eversense can sign up at www.eversensediabetes.com/get-started-today. Physicians, nurse practitioners or physician assistants interested in offering the Eversense CGM System for their patients can contact 844-SENSE4U (844-736-7348).

About Eversense

The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. Starting this fall, the system will be used to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements will still be required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://eversensediabetes.com/safety-info/.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

View Comments and Join the Discussion!